HALO
Price
$52.21
Change
-$0.32 (-0.61%)
Updated
Jun 27 closing price
Capitalization
6.44B
44 days until earnings call
IDYA
Price
$21.37
Change
-$0.92 (-4.13%)
Updated
Jun 27 closing price
Capitalization
1.87B
44 days until earnings call
Interact to see
Advertisement

HALO vs IDYA

Header iconHALO vs IDYA Comparison
Open Charts HALO vs IDYABanner chart's image
Halozyme Therapeutics
Price$52.21
Change-$0.32 (-0.61%)
Volume$21.4M
Capitalization6.44B
IDEAYA Biosciences
Price$21.37
Change-$0.92 (-4.13%)
Volume$3.2M
Capitalization1.87B
HALO vs IDYA Comparison Chart in %
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. IDYA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Buy and IDYA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (HALO: $52.21 vs. IDYA: $21.37)
Brand notoriety: HALO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 755% vs. IDYA: 248%
Market capitalization -- HALO: $6.44B vs. IDYA: $1.87B
HALO [@Biotechnology] is valued at $6.44B. IDYA’s [@Biotechnology] market capitalization is $1.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • HALO’s TA Score: 3 bullish, 2 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HALO is a better buy in the short-term than IDYA.

Price Growth

HALO (@Biotechnology) experienced а -1.14% price change this week, while IDYA (@Biotechnology) price change was -1.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

HALO is expected to report earnings on Aug 12, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($6.44B) has a higher market cap than IDYA($1.87B). HALO YTD gains are higher at: 9.203 vs. IDYA (-16.848). HALO has higher annual earnings (EBITDA): 705M vs. IDYA (-356.46M). HALO has more cash in the bank: 748M vs. IDYA (693M). IDYA has less debt than HALO: IDYA (26M) vs HALO (1.51B). HALO has higher revenues than IDYA: HALO (1.08B) vs IDYA (7M).
HALOIDYAHALO / IDYA
Capitalization6.44B1.87B344%
EBITDA705M-356.46M-198%
Gain YTD9.203-16.848-55%
P/E Ratio13.89N/A-
Revenue1.08B7M15,486%
Total Cash748M693M108%
Total Debt1.51B26M5,796%
FUNDAMENTALS RATINGS
HALO vs IDYA: Fundamental Ratings
HALO
IDYA
OUTLOOK RATING
1..100
5271
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
4271
SMR RATING
1..100
1294
PRICE GROWTH RATING
1..100
6153
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is in the same range as HALO (75) in the Biotechnology industry. This means that IDYA’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (42) in the Biotechnology industry is in the same range as IDYA (71) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for IDYA (94) in the null industry. This means that HALO’s stock grew significantly faster than IDYA’s over the last 12 months.

IDYA's Price Growth Rating (53) in the null industry is in the same range as HALO (61) in the Biotechnology industry. This means that IDYA’s stock grew similarly to HALO’s over the last 12 months.

HALO's P/E Growth Rating (90) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that HALO’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOIDYA
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 13 days ago
68%
Bearish Trend 10 days ago
77%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
61%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLRTX10.240.06
+0.59%
NYLI Winslow Large Cap Growth Class R2
CEVYX12.500.05
+0.40%
Columbia Global Value Inst3
HSSCX23.660.07
+0.30%
Emerald Finance & Bking Innovt Fd C
DVRUX17.130.05
+0.29%
UBS US Dividend Ruler P
CZMSX15.630.01
+0.06%
Multi-Manager Small Cap Eq Strat Inst

HALO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with XENE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
-0.61%
XENE - HALO
43%
Loosely correlated
+0.62%
VIR - HALO
40%
Loosely correlated
-2.64%
ARGX - HALO
36%
Loosely correlated
+0.02%
IMCR - HALO
33%
Poorly correlated
N/A
IDYA - HALO
32%
Poorly correlated
-4.13%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-4.13%
IMNM - IDYA
61%
Loosely correlated
-0.23%
CGON - IDYA
60%
Loosely correlated
-0.46%
CRNX - IDYA
56%
Loosely correlated
-0.10%
DNLI - IDYA
56%
Loosely correlated
-2.69%
SYRE - IDYA
56%
Loosely correlated
-4.99%
More